BridgeBio Pharma, Inc. filings document a commercial-stage biopharmaceutical company focused on medicines for genetic conditions, including financial results, product revenue disclosures, program updates, and formal reports on ATTR-CM, LGMD2I/R9, and achondroplasia development programs.
Its SEC record includes Form 8-K disclosures for results of operations, Regulation FD presentations, clinical and regulatory press releases, material agreements, an at-the-market equity distribution agreement, convertible senior notes, and a board-authorized stock repurchase program. Proxy materials address director elections, executive compensation votes, auditor ratification, incentive plan share reserves, governance structure, and stockholder voting matters.
BridgeBio Pharma, Inc. (BBIO) – Form 144 filing dated 26 June 2025 discloses a proposed Rule 144 sale by Hannah Valantine & Denis von Kaeppler, who are identified as the spouse and joint owner of a member of the Board of Directors. The filing covers 1,542 common shares to be sold through Morgan Stanley Smith Barney on or about 26 June 2025 on Nasdaq, carrying an aggregate market value of $67,863.42. With 189,880,720 shares outstanding, the planned sale represents roughly 0.0008 % of shares outstanding.
The form also reports insider activity over the prior three months: four separate sales dated 10 June 2025, each involving 4,292 shares at gross proceeds of roughly $171.6 k apiece, totalling 17,168 shares and ~$686 k. All securities were originally acquired on 28 Dec 2021 via an open-market purchase paid in cash.
No adverse non-public information is acknowledged, and the signatory affirms compliance with Rule 144 representations. From a capital-markets perspective, the volumes involved are immaterial relative to BridgeBio’s float and should not affect liquidity or ownership structure in a meaningful way. Nevertheless, continued insider selling—even in small lots—can be interpreted by some investors as a sentiment cue and merits monitoring alongside future insider transaction patterns.
BridgeBio Pharma, Inc. (BBIO) – Form 144 filing dated 06/26/2025
An officer of BridgeBio Pharma, Hannah A. Valantine (joint tenancy with Denis Von Kaeppler), has filed a Form 144 giving notice of intent to sell 876 common shares through Morgan Stanley Smith Barney on or about 06/26/2025. At the last reported market price, the transaction is valued at $38,640.27.
Key details:
- Securities outstanding: 189,880,720 shares – the proposed sale equals roughly 0.0005 % of shares outstanding, indicating an immaterial impact on float.
- Acquisition history: The shares were originally purchased on 12/29/2021 in an open-market, cash transaction.
- Recent insider activity: In the past three months, the filer has executed four separate sales of 4,292 shares each (total 17,168 shares) generating about $686 k in gross proceeds. Even combined, these sales represent approximately 0.009 % of shares outstanding.
- Relationship to issuer: The filer is listed as an Officer; no additional role description is provided.
No material adverse information was asserted by the filer, and the signature attests compliance with Rule 144 and Rule 10b5-1 representations. The notice is classified as a LIVE submission.
Because the transaction size is de-minimis relative to the company’s capitalization, it is unlikely to influence valuation or liquidity. Nonetheless, investors monitoring insider sentiment may note the continuation of discretionary selling by an officer.
BridgeBio Pharma, Inc. (BBIO) filed a Form 144 on 06/26/2025 disclosing a proposed sale of 398 common shares by Ericka von Kaeppler & Denis von Kaeppler (joint tenants). The shares were originally acquired on 12/28/2021 through an open-market purchase for cash. Morgan Stanley Smith Barney LLC is listed as the executing broker and the transaction is slated for NASDAQ execution on or after 06/26/2025. At the filing date, BridgeBio had 189,880,720 shares outstanding, making the contemplated sale approximately 0.0002 % of total shares.
The filing also reports prior insider activity within the last three months: Hannah Valantine sold a total of 17,168 shares (four identical entries of 4,292 shares) on 06/10/2025, generating aggregate gross proceeds of roughly $686,363. No adverse information was acknowledged by the filer, and the customary Rule 144 representations were signed.
Overall, the notice documents routine insider selling of a very small stake with negligible impact on the company’s share structure.
BridgeBio Pharma (BBIO) Director Andrew Lo reported new equity grants on June 20, 2025. The insider received:
- 6,589 Restricted Stock Units (RSUs) with zero acquisition cost, vesting over three years through June 20, 2028
- 8,425 Stock Options with a strike price of $41.73, exercisable until June 19, 2035, also vesting over three years
Following these transactions, Lo owns 54,688 shares directly and 105,583 shares indirectly through joint ownership with Nancy N. Lo. The equity grants are subject to continued service on the board. These awards were granted under the company's 2021 Amended and Restated Stock Option and Incentive Plan, representing standard director compensation rather than open market transactions.
BridgeBio Pharma director Andrea Ellis received new equity compensation grants on June 20, 2025, consisting of two components:
- 6,589 Restricted Stock Units (RSUs) with a $0 exercise price, increasing total direct stock ownership to 18,589 shares
- 8,425 Stock Options with an exercise price of $41.73 and expiration date of June 19, 2035
Both grants follow a 3-year vesting schedule with one-third vesting annually starting June 20, 2025, contingent on continued board service through June 20, 2028. The equity awards were issued under the company's 2021 Amended and Restated Stock Option and Incentive Plan, representing standard director compensation aligned with long-term shareholder interests.
BridgeBio Pharma director Jennifer E. Cook received new equity compensation grants on June 20, 2025, consisting of:
- 6,589 Restricted Stock Units (RSUs) with a $0 exercise price, bringing her total direct RSU ownership to 13,741 shares
- 8,425 Stock Options with an exercise price of $41.73 per share, expiring June 19, 2035
Both grants follow a 3-year vesting schedule with one-third vesting each year starting June 20, 2025, and completing on June 20, 2028. Vesting is contingent on Cook's continued service as a director. This Form 4 filing, signed on June 24, 2025, reflects standard equity compensation for non-employee directors and demonstrates the company's approach to aligning director interests with shareholders through long-term equity incentives.
BridgeBio Pharma Director Frank McCormick reported multiple equity transactions on June 20, 2025:
- Received 6,589 Restricted Stock Units (RSUs) with $0 exercise price, vesting over 3 years through June 20, 2028
- Granted 8,425 stock options with $41.73 exercise price, vesting over 3 years through June 20, 2028 and expiring June 19, 2035
- Currently holds 979,979 shares indirectly through the Francis P. McCormick Rev Trust
Both RSUs and options are subject to continued service on BridgeBio's board of directors. The grants were made under the company's 2021 Amended and Restated Stock Option and Incentive Plan. Each RSU represents the right to receive one share of common stock upon vesting.
BridgeBio Pharma Director Eric Aguiar reported two significant equity transactions on June 20, 2025:
- Restricted Stock Units (RSUs): Acquired 6,589 RSUs at $0 cost, which vest over three years through June 20, 2028
- Stock Options: Received 8,425 options with exercise price of $41.73, vesting over three years and expiring June 19, 2035
Both grants are subject to Aguiar's continued service on BridgeBio's board of directors, with annual vesting of one-third of the awards. The RSUs represent contingent rights to receive common stock shares upon vesting. This compensation package aligns the director's interests with long-term shareholder value through a combination of time-based RSUs and options with a significant exercise price.
BridgeBio Pharma director Ronald J. Daniels received new equity compensation grants on June 20, 2025, consisting of:
- 6,589 Restricted Stock Units (RSUs) with a $0 exercise price, bringing total direct RSU ownership to 16,991 units
- 8,425 Stock Options with an exercise price of $41.73 per share
Both grants follow a 3-year vesting schedule with one-third vesting annually from June 20, 2025 through June 20, 2028, contingent on continued board service. The stock options expire on June 19, 2035. These grants were made under the company's 2021 Amended and Restated Stock Option and Incentive Plan, representing standard director compensation aligned with long-term shareholder interests.
BridgeBio Pharma Director Ali J. Satvat reported two significant equity transactions on June 20, 2025:
- Received 6,589 restricted stock units (RSUs) at $0, bringing total direct ownership to 165,993 shares. RSUs vest over three years through June 20, 2028
- Granted stock options to purchase 8,425 shares at an exercise price of $41.73 per share, expiring June 19, 2035
Both grants are subject to continued service on the board and follow a three-year vesting schedule, with one-third vesting each year starting June 20, 2025. The transactions were executed under the company's 2021 Amended and Restated Stock Option and Incentive Plan. Satvat serves as a Director but is not a 10% owner of BridgeBio Pharma.